HK Stock Market Move | Cssc Offshore & Marine Engineering (00317) rose over 4% during trading. In the first half of the year, the net profit attributable to the parent company increased by 59% year-on-year, with shipbuilding orders on hand totaling 73.4 billion yuan.
China Shipbuilding Defense (00317) rose over 4% during the trading session. As of the time of writing, it is up 3.41%, priced at HKD 12.73, with a trading volume of HKD 39.3977 million.
Cssc Offshore & Marine Engineering (00317) surged over 4% during intraday trading. As of the time of writing, the stock rose by 3.41% to HKD 12.73, with a trading volume of HKD 39.3977 million.
In terms of news, Cssc Offshore & Marine Engineering recently released its half-year report for 2026, reporting a net profit attributable to shareholders of RMB 840 million in the first half of the year, a year-on-year increase of 59%. For the second quarter alone, the net profit attributable to shareholders was RMB 440 million, representing a 29% year-on-year increase and an 11% quarter-on-quarter increase. The company currently has a shipbuilding order backlog worth RMB 73.4 billion, including 173 vessels and 1 piece of offshore engineering equipment, totaling 6.28 million deadweight tons. Shenwan Hongyuan Group indicated that the company continues to benefit from high prosperity in the shipbuilding industry, with ample orders on hand and ongoing implementation of high-value-added ship type orders, maintaining a "buy" rating.
Related Articles

How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.

RECOMMEND





